Key result
Sitagliptin treatment for 26 weeks did not improve endothelial cell function, as assessed by flow-mediated dilation, compared to glimepiride in patients with type 2 diabetes mellitus.
Why the study?
Does sitagliptin improve endothelial cell function in patients with type 2 diabetes mellitus?
Does sitagliptin improve endothelial cell function in patients with type 2 diabetes mellitus?
Sitagliptin does not directly improve endothelial function in patients with type 2 diabetes, but it may have beneficial effects on beta-cell function and anti-oxidant potentials.
Sitagliptin confers no endothelial benefit versus glimepiride in T2DM; leaves open potential effects on beta-cell function and oxidative stress.
DPP-4 inhibitors have been used to treat patients with type 2 diabetes mellitus.These agents not only provide glycemic control, but also have other favorable effects, including the prevention of atherosclerosis.However, it has not been determined whether these agents can improve or maintain endothelial cell function.We previously reported the results of two prospective studies assessing the effects of incretin agents on flow-mediated dilation in patients with type 2 diabetes mellitus without severe atherosclerotic diseases.These studies showed that both the DPP-4 inhibitor sitagliptin and the GLP-1 analogue liraglutide did not improve endothelial cell function.This report discusses the effects of sitagliptin on early-stage atherosclerosis and beta-cell function.
No takes yet. Share an insight, caveat, or question.
Nomoto et al. (2017) conducted a review in Type 2 diabetes mellitus. Sitagliptin vs. Glimepiride (0.5-2.0 mg/day) was evaluated on Endothelial cell function assessed by flow-mediated dilation (FMD). Sitagliptin treatment for 26 weeks did not improve endothelial cell function, as assessed by flow-mediated dilation, compared to glimepiride in patients with type 2 diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: